Sankyo Company, Limited

Snow Brand Milk Products Co., Ltd.

Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Masatsugu Ueda

Kanji Higashio

Masaaki Goto

Eisuke Tsuda

Fumie Kobayashi

Nobuyuki Shima

Kazuki Yano

Tomonori Morinaga

Nobuaki Nakagawa

Hisataka Yasuda

Shin'ichi Mochizuki

Kyoji Yamaguchi

Akihiko Murakami

Eitaro Kumazawa

Masahiko Kinosaki

Naohiro Washida

Hiroaki Masunaga

Fumiko Oogaki

Yasushi Yamashita

Hideo Chiba

Ryuzo Sasaki

Toshiko Satake

Takashi Mano

Nobuyuki Kawashima

Hitoshi Hayasaka

Reiko Takahira

Shin′ichi Mochizuki

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein

Proteins and methods for producing the proteins

A protein which inhibits osteoclast diffraction and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Monoclonal antibodies that bind OCIF

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis[[, respectively]]. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

The present invention relates to a TCF mutant having a novel amino acid sequence which is obtained by mutagenesis of one or more amino acid between N-terminus and the first kringle of the amino acid sequence of native TCF and has lowered affinity to heparin and/or elevated biological activity. The present TCF mutant is prepared by gene manipulation of TCF. The TCF mutants of the present invention have proliferative activity and/or growth stimulative activity in hepatocyte and beneficial as a therapeutic agent for various hepatic diseases and an antitumor agent.

TCF mutant

Basic osteoblast growth factor II (bOGF-II)

Modified tumor cytotoxic factor (TCF) and DNA encoding such

This invention provides pharmaceutical preparations containing highly concentrated tumor cytotoxic factor (TCF). The pharmaceutical preparations of the present invention contain highly concentrated TCF and a basic amino acid or their salts, or an organic or inorganic salt as a solubizer. The resultant compositions described in the present invention dissolve TCF at high concentrations of 10 mg/ml or over under about neutral and isotonic conditions. The resultant compositions are stable and are suitable for injection preparations.

Highly concentrated TCF pharmaceutical preparations

Here is disclosed a cell culture tank comprising a cylindrical screen mounted upright within the cell culture tank and having upper and lower openings through which culture medium flows, a pipe for supply of oxygen or oxygen containing gas and an agitator adapted to produce a flow of the culture medium, both the pipe and the agitator being provided within the cylindrical screen, wherein the agitator drives the culture medium to flow downward through the lower opening of the cylindrical screen, then to flow upward into a space defined between the cylindrical screen and the inner wall of the cell culture tank, and a relationship between an ascending velocity of the culture medium and a sinking velocity of the adherent carriers produces in the space between the cylindrical screen and the inner wall of the cell culture tank a floating region within which the adherent carriers float in the culture medium and a separating region within which the adherent carriers are separated from the culture medium.

Cell culture tank

Disclosed herein is a process for producing erythropoietin, comprising bringing a material containing erythropoietin into contact with an adsorbent having a monoclonal anti-erythropoietin antibody, adsorbing erythropoietin on the adsorbent, and eluting the absorbed erythropoietin from the adsorbent.

Process for producing erythropoietin

Growing community of inventors

Kawagoe, Japan

Masatsugu Ueda